Navigation Links
Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections

Data on frequency of resistance development and safety presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SAN DIEGO, May 18 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced new data today from multiple studies of torezolid (TR-701), a novel antibiotic that is a potent inhibitor of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Data presented at ECCMID demonstrate that MRSA and MSSA strains exposed in vitro to torezolid developed spontaneous resistance at a 16-fold lower frequency than strains exposed to linezolid (Zyvox(R)), the only drug of the oxazolidinone class currently marketed. Poster presentations on TR-701 also highlighted data characterizing torezolid's pharmacodynamics, high intracellular concentrations and resulting bactericidal activity. Human Phase 1 clinical studies showed that oral torezolid, administered at doses from 200 to 400 mg once a day over 21 days, is safe and well tolerated, and that its oral bioavailability is not affected by the administration of food.

"These new study results presented by Trius and external investigators validate the compound's increased potency and ability to reach bacterial pathogens in high concentration inside the tissues while also supporting a favorable safety and tolerability profile," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "As a result, there is significant interest from the medical community in torezolid, a second generation oxazolidinone, especially for the treatment of infections caused by S. aureus, including MRSA."

Posters/abstracts are available on the Trius Web site at

"As bacterial pathogens like MRSA continue developing resistance to current treatments, clinicians are more acutely aware of the need for an alternative that is less susceptible to resistance development along with a once a day dosing regimen which promotes higher compliance," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We will release top-line Phase 2 data in the coming weeks and plan to initiate Phase 3 testing in early 2010. Our goal is to provide physicians and patients with a best-in-class therapy as soon as possible."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by gram-negative bacterial pathogens. For more information, visit

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Atrius Health Selects rL Solutions for Improved Patient Safety and Quality of Care
2. Trius Raises $30 Million in Series B Financing
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
5. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
6. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
7. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
8. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
9. American Association for Homecare Applauds Senate Subcommittee Efforts to Prevent Waste and Fraud in Medicare; Association Presents 13-Point Legislative Plan to Stop Waste and Fraud
10. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: